FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995438247> ?p ?o ?g. }

• W1995438247 endingPage "154" @default.
• W1995438247 startingPage "149" @default.
• W1995438247 abstract "The REPLACE-2 trial demonstrated that bivalirudin with provisional glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition is not inferior to heparin plus GPIIb/IIIa inhibition in patients undergoing percutaneous coronary intervention. The extent to which this applies to patients with acute coronary syndromes (ACS) is unclear. Therefore, we sought to determine if bivalirudin has similar efficacy in ACS patients as compared with “stable” patients in the REPLACE-2 trial. We analyzed the outcomes of ACS patients compared with stable patients and the outcomes of ACS patients according to whether or not they had received bivalirudin, including the economic costs. The trial enrolled 1351 ACS patients (myocardial infarction within 7 days or unstable angina within 48 hours, but not on ongoing GPIIb/IIIa or heparin therapy) and 4554 stable patients. Patients with ACS had a similar rate of death or myocardial infarction at 30 days compared to stable patients (7.2% vs 6.7%, P = .51) and death at 1 year (1.6% vs 2.2%, P = .169), but a higher rate of urgent coronary artery bypass graft at 30 days (1.0% vs 0.3%, P = .002). Patients with ACS treated with bivalirudin had a similar rate of 30-day death, myocardial infarction, or urgent revascularization compared with ACS patients treated with heparin and GPIIb/IIIa inhibitors (8.7% vs 8.0%, P = .616) and death at 1 year (1.5% vs 1.8%, P = .701), but a higher rate of revascularization at 6 months (12% vs 8.4%, P = .04). Patients with ACS treated with bivalirudin had less major bleeding than ACS patients treated with heparin and GPIIb/IIIa inhibitors, although this was not statistically significant (2.7% vs 4.5%, P = .07). Mean 30-day costs for patients with ACS were $12 415 for those treated with bivalirudin and $12 806 for those treated with heparin plus GPIIb/IIIa inhibitors (P = .022). Bivalirudin with provisional GPIIb/IIIa inhibitor use in low-risk ACS patients (not receiving preprocedural GPIIb/IIIa blockade) appears to provide similar protection against death and myocardial infarction as the combination of heparin and GPIIb/IIIa inhibitors, although we observed a higher rate of revascularization at 6 months." @default.
• W1995438247 created "2016-06-24" @default.
• W1995438247 creator A5011091435 @default.
• W1995438247 creator A5029768994 @default.
• W1995438247 creator A5034471719 @default.
• W1995438247 creator A5039754301 @default.
• W1995438247 creator A5050863307 @default.
• W1995438247 creator A5063647384 @default.
• W1995438247 creator A5065412099 @default.
• W1995438247 creator A5086611754 @default.
• W1995438247 creator A5087317612 @default.
• W1995438247 creator A5087577528 @default.
• W1995438247 date "2006-07-01" @default.
• W1995438247 modified "2023-09-27" @default.
• W1995438247 title "Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial" @default.
• W1995438247 cites W1489918304 @default.
• W1995438247 cites W2006935825 @default.
• W1995438247 cites W2035144106 @default.
• W1995438247 cites W2046359098 @default.
• W1995438247 cites W2077401512 @default.
• W1995438247 cites W2102296549 @default.
• W1995438247 cites W2115014977 @default.
• W1995438247 cites W2130652855 @default.
• W1995438247 cites W2138787652 @default.
• W1995438247 cites W2138804305 @default.
• W1995438247 cites W2138849164 @default.
• W1995438247 cites W2335915210 @default.
• W1995438247 cites W2395313915 @default.
• W1995438247 cites W3022148767 @default.
• W1995438247 doi "https://doi.org/10.1016/j.ahj.2005.09.007" @default.
• W1995438247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16824845" @default.
• W1995438247 hasPublicationYear "2006" @default.
• W1995438247 type Work @default.
• W1995438247 sameAs 1995438247 @default.
• W1995438247 citedByCount "30" @default.
• W1995438247 countsByYear W19954382472012 @default.
• W1995438247 countsByYear W19954382472013 @default.
• W1995438247 countsByYear W19954382472015 @default.
• W1995438247 countsByYear W19954382472016 @default.
• W1995438247 countsByYear W19954382472022 @default.
• W1995438247 crossrefType "journal-article" @default.
• W1995438247 hasAuthorship W1995438247A5011091435 @default.
• W1995438247 hasAuthorship W1995438247A5029768994 @default.
• W1995438247 hasAuthorship W1995438247A5034471719 @default.
• W1995438247 hasAuthorship W1995438247A5039754301 @default.
• W1995438247 hasAuthorship W1995438247A5050863307 @default.
• W1995438247 hasAuthorship W1995438247A5063647384 @default.
• W1995438247 hasAuthorship W1995438247A5065412099 @default.
• W1995438247 hasAuthorship W1995438247A5086611754 @default.
• W1995438247 hasAuthorship W1995438247A5087317612 @default.
• W1995438247 hasAuthorship W1995438247A5087577528 @default.
• W1995438247 hasConcept C126322002 @default.
• W1995438247 hasConcept C164705383 @default.
• W1995438247 hasConcept C2777557582 @default.
• W1995438247 hasConcept C2777565915 @default.
• W1995438247 hasConcept C2777698277 @default.
• W1995438247 hasConcept C2777785093 @default.
• W1995438247 hasConcept C2779464278 @default.
• W1995438247 hasConcept C2780400711 @default.
• W1995438247 hasConcept C45393284 @default.
• W1995438247 hasConcept C500558357 @default.
• W1995438247 hasConcept C71924100 @default.
• W1995438247 hasConceptScore W1995438247C126322002 @default.
• W1995438247 hasConceptScore W1995438247C164705383 @default.
• W1995438247 hasConceptScore W1995438247C2777557582 @default.
• W1995438247 hasConceptScore W1995438247C2777565915 @default.
• W1995438247 hasConceptScore W1995438247C2777698277 @default.
• W1995438247 hasConceptScore W1995438247C2777785093 @default.
• W1995438247 hasConceptScore W1995438247C2779464278 @default.
• W1995438247 hasConceptScore W1995438247C2780400711 @default.
• W1995438247 hasConceptScore W1995438247C45393284 @default.
• W1995438247 hasConceptScore W1995438247C500558357 @default.
• W1995438247 hasConceptScore W1995438247C71924100 @default.
• W1995438247 hasIssue "1" @default.
• W1995438247 hasLocation W19954382471 @default.
• W1995438247 hasLocation W19954382472 @default.
• W1995438247 hasOpenAccess W1995438247 @default.
• W1995438247 hasPrimaryLocation W19954382471 @default.
• W1995438247 hasRelatedWork W1523672392 @default.
• W1995438247 hasRelatedWork W2006663006 @default.
• W1995438247 hasRelatedWork W2074910852 @default.
• W1995438247 hasRelatedWork W2324693508 @default.
• W1995438247 hasRelatedWork W2358791623 @default.
• W1995438247 hasRelatedWork W2376962719 @default.
• W1995438247 hasRelatedWork W2382579536 @default.
• W1995438247 hasRelatedWork W2415979713 @default.
• W1995438247 hasRelatedWork W2593799290 @default.
• W1995438247 hasRelatedWork W2766678702 @default.
• W1995438247 hasVolume "152" @default.
• W1995438247 isParatext "false" @default.
• W1995438247 isRetracted "false" @default.
• W1995438247 magId "1995438247" @default.
• W1995438247 workType "article" @default.